TY - JOUR
T1 - Gender-based analysis of pre-residency research productivity among a current United States radiation oncology resident class
AU - McClelland, Shearwood
AU - Murphy, Blair
AU - Jaboin, Jerry J.
AU - Zellars, Richard C.
N1 - Publisher Copyright:
© Chinese Clinical Oncology. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Background: The increasing proportion of women in medicine has not been adequately reflected in the gender distribution of radiation oncology residents. The presence of at least one pre-residency peer-reviewed publication (PRP) has been associated with radiation oncology resident choice of academic over private practice career, with no significant gender difference in the likelihood of having a PRP (McClelland et al., 2017). We sought to pursue a gender-based analysis of PRP productivity in a current junior resident class. Methods: A list of radiation oncology residents from the graduating class of 2022 (PGY-2 academic year of 2018-2019) was obtained through internet investigation. Research productivity was calculated using PRP number, defined as the number of a resident's publications listed in PubMed (pubmed.gov) through the calendar year of residency application (2016 for this class). Results: Of 195 residents examined from the 2022 class, 61 (31%) were women, representing a nine percent increase from the resident class of 2016. Four-fifths of women had 1+ PRP, 31% had dual degrees, and 18% had a PhD. These percentages were comparable to their male counterparts, 73% with 1+ PRP, 28% with dual degrees, and 15% with a PhD. There were no statistically significant differences by gender in any of these benchmarks. Conclusions: While slower than the overall trend of increased female representation in medicine, the proportion of women in radiation oncology residency has increased by 0.9-1.5% annually over a recent six-year span. There remain no significant differences in PRP productivity, dual degree status, or PhD status by gender.
AB - Background: The increasing proportion of women in medicine has not been adequately reflected in the gender distribution of radiation oncology residents. The presence of at least one pre-residency peer-reviewed publication (PRP) has been associated with radiation oncology resident choice of academic over private practice career, with no significant gender difference in the likelihood of having a PRP (McClelland et al., 2017). We sought to pursue a gender-based analysis of PRP productivity in a current junior resident class. Methods: A list of radiation oncology residents from the graduating class of 2022 (PGY-2 academic year of 2018-2019) was obtained through internet investigation. Research productivity was calculated using PRP number, defined as the number of a resident's publications listed in PubMed (pubmed.gov) through the calendar year of residency application (2016 for this class). Results: Of 195 residents examined from the 2022 class, 61 (31%) were women, representing a nine percent increase from the resident class of 2016. Four-fifths of women had 1+ PRP, 31% had dual degrees, and 18% had a PhD. These percentages were comparable to their male counterparts, 73% with 1+ PRP, 28% with dual degrees, and 15% with a PhD. There were no statistically significant differences by gender in any of these benchmarks. Conclusions: While slower than the overall trend of increased female representation in medicine, the proportion of women in radiation oncology residency has increased by 0.9-1.5% annually over a recent six-year span. There remain no significant differences in PRP productivity, dual degree status, or PhD status by gender.
KW - Gender equity
KW - Pre-residency peer-reviewed publications (PRP)
KW - Radiation oncology residents
KW - Research productivity
UR - http://www.scopus.com/inward/record.url?scp=85120341736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120341736&partnerID=8YFLogxK
U2 - 10.21037/cco-21-95
DO - 10.21037/cco-21-95
M3 - Article
C2 - 34749504
AN - SCOPUS:85120341736
VL - 10
JO - Chinese Clinical Oncology
JF - Chinese Clinical Oncology
SN - 2304-3865
IS - 5
M1 - 52
ER -